TFX

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the successful completion of patient enrollment in the BIOMAG™-LL Clinical Study, evaluating the safety and clinical performance of the Freesolve™ Resorbable Magnesium Scaffold (RMS) in 35 mm and 40 mm lengths for the treatment of de novo coronary lesions up to 38 mm. The study reflects Teleflex's commitment to expanding clinical evidence supporting the use of the F.

Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and SONOVA HOLDING (SONVY). But which of these two stocks offers value investors a better bang for their buck right now?

TFX's Vascular growth, Asia expansion and improved leverage support the outlook, but tariffs, input costs and margin pressure remain key risks.

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the publication of its latest peer-reviewed study in the American Journal of Infection Control demonstrating that Central Venous Catheters (CVCs) protected with Arrowg+ard™ Technology were associated with a statistically significant 70% lower hazard of central line-associated bloodstream infections (CLABSIs) compared with plain, non-impregnated catheters during a 30.

Teleflex (TFX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

TFX, CNC, ENS, ROCK and FAF stand out among five low P/B stocks offering attractive value and promising growth prospects.

Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and Penumbra (PEN). But which of these two stocks is more attractive to value investors?

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the appointment of Sean M. Salmon to its Board of Directors, effective September 8, 2026. Mr. Salmon brings over three decades of global leadership experience in the medical device and pharmaceutical industries, culminating in more than 20 years at Medtronic plc (NYSE: MDT). He most recently served as Executive Vice President and President of its Cardiovascular Portf.

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it will showcase innovative technologies at CIRSE 2026 in Copenhagen, reinforcing its commitment to advancing innovation for healthcare providers. Among the featured technologies will be the Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System. This technology is supported by the previously presented BIONETIC-TRA study, an investigator-initiated study with a.